Megan Meyer New Article in the Baltimore Sun
Last month in Denver, an estimated 10,000 scientists, clinicians, CEOs and entrepreneurs convened for the Psychedelic Science 2023 conference — the most visible symbol yet of the “psychedelic renaissance.”
Scientific research is demonstrating the potential of psychedelic-assisted therapy (PAT) to treat a range of mental health conditions, including addiction, major depressive disorder, anxiety and post-traumatic stress disorder. Ketamine therapy is increasingly widespread, and the Food and Drug Administration seems poised to approve the therapeutic use of both methylenedioxymethamphetamine (MDMA) and psilocybin in the next couple of years.
Read the full article at this link.